A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Osama E. Rahma, Ed Ashtar, Ramy Ibrahim, Antoun Toubaji, Barry Gause, Vincent E. Herrin, W. Marston Linehan, Seth M. Steinberg, Frank Grollman, George Grimes, Sarah A. Bernstein, Jay A. Berzofsky, Samir N. Khleif

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides.Methods: Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until disease progression or until the utilization of all available peptide stock.Results: Four out of five evaluable patients (80%) generated specific immune responses against the corresponding mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively.Conclusions: The vaccine demonstrated safety and proved efficacy in generating specific immune response to the mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the utilization of VHL as a vaccine target presents a promising approach because of the lack of other specific targets for RCC. Accordingly, developing mutant VHL peptides as vaccines for RCC warrants further investigation in larger trials. Trial registration: 98C0139.

Original languageEnglish (US)
Article number8
JournalJournal of Translational Medicine
Volume8
DOIs
StatePublished - Jan 28 2010

Fingerprint

Renal Cell Carcinoma
Cells
Clinical Trials
Vaccines
Peptides
Testing
Therapeutics
Genes
Cancer Vaccines
Subunit Vaccines
Neoplasm Antigens
Disease-Free Survival
Toxicity
Disease Progression
Tumors
Safety
Mutation
Survival
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. / Rahma, Osama E.; Ashtar, Ed; Ibrahim, Ramy; Toubaji, Antoun; Gause, Barry; Herrin, Vincent E.; Linehan, W. Marston; Steinberg, Seth M.; Grollman, Frank; Grimes, George; Bernstein, Sarah A.; Berzofsky, Jay A.; Khleif, Samir N.

In: Journal of Translational Medicine, Vol. 8, 8, 28.01.2010.

Research output: Contribution to journalArticle

Rahma, OE, Ashtar, E, Ibrahim, R, Toubaji, A, Gause, B, Herrin, VE, Linehan, WM, Steinberg, SM, Grollman, F, Grimes, G, Bernstein, SA, Berzofsky, JA & Khleif, SN 2010, 'A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma', Journal of Translational Medicine, vol. 8, 8. https://doi.org/10.1186/1479-5876-8-8
Rahma, Osama E. ; Ashtar, Ed ; Ibrahim, Ramy ; Toubaji, Antoun ; Gause, Barry ; Herrin, Vincent E. ; Linehan, W. Marston ; Steinberg, Seth M. ; Grollman, Frank ; Grimes, George ; Bernstein, Sarah A. ; Berzofsky, Jay A. ; Khleif, Samir N. / A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. In: Journal of Translational Medicine. 2010 ; Vol. 8.
@article{f614028851aa477088b3e0184e3df9a1,
title = "A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma",
abstract = "Background: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides.Methods: Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until disease progression or until the utilization of all available peptide stock.Results: Four out of five evaluable patients (80{\%}) generated specific immune responses against the corresponding mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively.Conclusions: The vaccine demonstrated safety and proved efficacy in generating specific immune response to the mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the utilization of VHL as a vaccine target presents a promising approach because of the lack of other specific targets for RCC. Accordingly, developing mutant VHL peptides as vaccines for RCC warrants further investigation in larger trials. Trial registration: 98C0139.",
author = "Rahma, {Osama E.} and Ed Ashtar and Ramy Ibrahim and Antoun Toubaji and Barry Gause and Herrin, {Vincent E.} and Linehan, {W. Marston} and Steinberg, {Seth M.} and Frank Grollman and George Grimes and Bernstein, {Sarah A.} and Berzofsky, {Jay A.} and Khleif, {Samir N.}",
year = "2010",
month = "1",
day = "28",
doi = "10.1186/1479-5876-8-8",
language = "English (US)",
volume = "8",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

AU - Rahma, Osama E.

AU - Ashtar, Ed

AU - Ibrahim, Ramy

AU - Toubaji, Antoun

AU - Gause, Barry

AU - Herrin, Vincent E.

AU - Linehan, W. Marston

AU - Steinberg, Seth M.

AU - Grollman, Frank

AU - Grimes, George

AU - Bernstein, Sarah A.

AU - Berzofsky, Jay A.

AU - Khleif, Samir N.

PY - 2010/1/28

Y1 - 2010/1/28

N2 - Background: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides.Methods: Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until disease progression or until the utilization of all available peptide stock.Results: Four out of five evaluable patients (80%) generated specific immune responses against the corresponding mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively.Conclusions: The vaccine demonstrated safety and proved efficacy in generating specific immune response to the mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the utilization of VHL as a vaccine target presents a promising approach because of the lack of other specific targets for RCC. Accordingly, developing mutant VHL peptides as vaccines for RCC warrants further investigation in larger trials. Trial registration: 98C0139.

AB - Background: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides.Methods: Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until disease progression or until the utilization of all available peptide stock.Results: Four out of five evaluable patients (80%) generated specific immune responses against the corresponding mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively.Conclusions: The vaccine demonstrated safety and proved efficacy in generating specific immune response to the mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the utilization of VHL as a vaccine target presents a promising approach because of the lack of other specific targets for RCC. Accordingly, developing mutant VHL peptides as vaccines for RCC warrants further investigation in larger trials. Trial registration: 98C0139.

UR - http://www.scopus.com/inward/record.url?scp=77649326673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649326673&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-8-8

DO - 10.1186/1479-5876-8-8

M3 - Article

C2 - 20109232

AN - SCOPUS:77649326673

VL - 8

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 8

ER -